Tesetaxel

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tesetaxel
Tesetaxel.png
Clinical data
ATC code none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 333754-36-2 YesY
PubChem (CID) 6918574
ChemSpider 5293771 N
UNII UG97LO5M8Y YesY
Chemical and physical data
Formula C46H60FN3O13
Molar mass 881.98 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Tesetaxel (DJ-927) is a drug being investigated for chemotherapy of various types of cancer, including breast cancer,[1] gastric cancer,[2] and other solid tumours.[3]

References[edit]

  1. ^ Clinical trial number NCT01609127 for "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT01348009 for "Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer" at ClinicalTrials.gov
  3. ^ Saif, M. W.; Sarantopoulos, J.; Patnaik, A.; Tolcher, A. W.; Takimoto, C.; Beeram, M. (2011). "Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (6): 1565–1573. doi:10.1007/s00280-011-1639-3. PMID 21547572.